|
Sections |
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents
The Vaccines Market Outlook To 2014
Executive summary 10
Vaccines and vaccine-preventable diseases 10
Overview of the global vaccines market 11
Pediatric vaccines 12
Adult vaccines 13
Pipeline analysis 14
Competitive landscape 15
Chapter | 0 | 1 |
| Table of Contents | 0 | 1 |
| The Vaccines Market Outlook To 2014 | 0 | 1 |
| Executive summary 10 | 0 | 1 |
| Vaccines and vaccine-preventable diseases 10 | 0 | 1 |
| Overview of the global vaccines market 11 | 0 | 1 |
| Pediatric vaccines 12 | 0 | 1 |
| Adult vaccines 13 | 0 | 1 |
| Pipeline analysis 14 | 0 | 1 |
| Competitive landscape 15 | 0 | 1 |
| Chapter 1 Scope and methodology 18 | 0 | 1 |
| Scope 18 | 0 | 1 |
| Methodology 19 | 0 | 1 |
| Chapter 2 Vaccines and vaccine-preventable diseases 22 | 0 | 1 |
| Summary 22 | 0 | 1 |
| Introduction 23 | 0 | 1 |
| Vaccines and the immune system 23 | 0 | 1 |
| The immune system 23 | 0 | 1 |
| Immunity by vaccination 24 | 0 | 1 |
| The history of vaccination 24 | 0 | 1 |
| Types of vaccines 26 | 0 | 1 |
| Hurdles in vaccine development 27 | 0 | 1 |
| Vaccine-preventable diseases 29 | 0 | 1 |
| Measles 29 | 0 | 1 |
| Mumps 30 | 0 | 1 |
| Rubella 30 | 0 | 1 |
| Diphtheria 31 | 0 | 1 |
| Tetanus 31 | 0 | 1 |
| Pertussis 32 | 0 | 1 |
| Meningitis (pneumococcus, meningococcus and Hib) 32 | 0 | 1 |
| Varicella 33 | 0 | 1 |
| Hepatitis 33 | 0 | 1 |
| Influenza 34 | 0 | 1 |
| Typhoid 35 | 0 | 1 |
| Rabies 35 | 0 | 1 |
| Chapter 3 Overview of the global vaccines market 38 | 0 | 1 |
| Summary 38 | 0 | 1 |
| Introduction 39 | 0 | 1 |
| Key trends, issues and events 39 | 0 | 1 |
| Prophylactic cancer vaccines redefine the market 39 | 0 | 1 |
| US health reforms and VFC recommendations may influence vaccines sales 40 | 0 | 1 |
| Therapeutic vaccines: a franchise in the making 40 | 0 | 1 |
| Cell culture and adjuvant technology: next-generation vaccine engineering 41 | 0 | 1 |
| Seasonal influenza vaccines: key to continuous revenue generation 42 | 0 | 1 |
| Novel combination vaccines driving growth of vaccines for infectious diseases 42 | 0 | 1 |
| Leading vaccine brands 44 | 0 | 1 |
| Sales forecasts of leading vaccine brands 45 | 0 | 1 |
| Country market analysis 47 | 0 | 1 |
| Leading players in the vaccines market 48 | 0 | 1 |
| Chapter 4 Pediatric vaccines 50 | 0 | 1 |
| Summary 50 | 0 | 1 |
| Introduction 51 | 0 | 1 |
| Pediatric immunization schedule 51 | 0 | 1 |
| Pediatric vaccine population 53 | 0 | 1 |
| Pneumococcal vaccines 54 | 0 | 1 |
| Leading brands 55 | 0 | 1 |
| Competitive analysis 55 | 0 | 1 |
| Diphtheria, tetanus and pertussis (DTP) vaccines 56 | 0 | 1 |
| Leading brands 57 | 0 | 1 |
| Competitive analysis 57 | 0 | 1 |
| Measles, mumps and rubella (MMR) vaccines 58 | 0 | 1 |
| Leading brands 59 | 0 | 1 |
| Competitive analysis 60 | 0 | 1 |
| Market transition from MMR to MMRV 60 | 0 | 1 |
| Rotaviral vaccines 62 | 0 | 1 |
| Leading rotaviral vaccine brands 63 | 0 | 1 |
| Competitive analysis 63 | 0 | 1 |
| Meningococcal vaccines 64 | 0 | 1 |
| Leading meningococcal vaccine brands 65 | 0 | 1 |
| Competitive analysis 65 | 0 | 1 |
| Other pediatric vaccines 67 | 0 | 1 |
| Leading brands 67 | 0 | 1 |
| Competitive analysis 68 | 0 | 1 |
| Chapter 5 Adult vaccines 72 | 0 | 1 |
| Summary 72 | 0 | 1 |
| Introduction 73 | 0 | 1 |
| Adult vaccine population 74 | 0 | 1 |
| Adolescent vaccination 74 | 0 | 1 |
| Elderly vaccination 75 | 0 | 1 |
| Traveler vaccination 75 | 0 | 1 |
| Hepatitis vaccines 76 | 0 | 1 |
| Leading brands 77 | 0 | 1 |
| Competitive analysis 78 | 0 | 1 |
| Influenza vaccines 79 | 0 | 1 |
| H1N1 swine flu 80 | 0 | 1 |
| Leading brands 81 | 0 | 1 |
| Competitive analysis 81 | 0 | 1 |
| Human papillomavirus (HPV) vaccines 82 | 0 | 1 |
| Leading brands 83 | 0 | 1 |
| Competitive analysis 83 | 0 | 1 |
| Other adult vaccines 86 | 0 | 1 |
| Leading brands 87 | 0 | 1 |
| Chapter 6 Pipeline analysis 90 | 0 | 1 |
| Summary 90 | 0 | 1 |
| Introduction 91 | 0 | 1 |
| Vaccines under research and development 91 | 0 | 1 |
| Prevnar 13vPnC 93 | 0 | 1 |
| Menveo 94 | 0 | 1 |
| MenB 95 | 0 | 1 |
| Cervarix 97 | 0 | 1 |
| Synflorix 98 | 0 | 1 |
| Ixiaro/Jespect 100 | 0 | 1 |
| Newer vaccine strategies: DNA and therapeutic vaccines 101 | 0 | 1 |
| DNA vaccines 101 | 0 | 1 |
| Therapeutic vaccines 102 | 0 | 1 |
| Provenge 106 | 0 | 1 |
| Pipeline forecasts 107 | 0 | 1 |
| Chapter 7 Competitive landscape 110 | 0 | 1 |
| Summary 110 | 0 | 1 |
| Introduction 111 | 0 | 1 |
| Market concentration/fragmentation analysis 111 | 0 | 1 |
| Segment wise positioning of the five major players 112 | 0 | 1 |
| Forecast sales of leading players in the global vaccines market, 2008–14 113 | 0 | 1 |
| Merck 113 | 0 | 1 |
| Overview 113 | 0 | 1 |
| Marketed portfolio 114 | 0 | 1 |
| Pipeline portfolio 114 | 0 | 1 |
| Licensing agreements/mergers/acquisitions 116 | 0 | 1 |
| Strategic and growth analysis 116 | 0 | 1 |
| GSK 119 | 0 | 1 |
| Overview 119 | 0 | 1 |
| Marketed portfolio 120 | 0 | 1 |
| Pipeline portfolio 121 | 0 | 1 |
| Licensing agreements/mergers/acquisitions 122 | 0 | 1 |
| Strategic and growth analysis 123 | 0 | 1 |
| Wyeth 126 | 0 | 1 |
| Overview 126 | 0 | 1 |
| Marketed portfolio 127 | 0 | 1 |
| Pipeline portfolio 127 | 0 | 1 |
| Licensing agreements/mergers/acquisitions 128
Strategic and growth analysis 129
Sanofi-Aventis 131
Overview 131
Marketed portfolio 131
Pipeline portfolio 132
Licensing agreements/mergers/acquisitions 135
Strategic and growth analysis 135
Novartis 139
Overv | 0 | 1 |
